Table IV.
Treatment | ERα | ERβ1 | PR | Ki-67 | uPAR |
---|---|---|---|---|---|
RPMI 5% FCS | +++ | +++ | +++ | +++ | − |
M1 CM | + | +++ | ++ | + | − |
M2 CM | + | +++ | +++ | ++ | − |
ERα, estrogen receptor α; ERβ1, estrogen receptor β1; PR, progesterone receptor; uPAR, urokinase-type plasminogen activator receptor. +++, very strong immunoreactivity; ++, strong immunoreactivity; +, weak immunoreactivity; −, negative immunoreactivity.